Useful info. Fortunate me I found your website accidentally, and I am surprised why this accident did not happened earlier! I bookmarked it. Review my site Malcolm Reply
Pretty great post. I simply stumbled upon your weblog and wanted to mention that I’ve truly loved browsing your weblog posts. After all I’ll be subscribing in your rss feed and I am hoping you write again very soon! Stop by my homepage 7khatcode.com Reply
Dr Michael R Hamblin Science and Research Advisor Michael R Hamblin Ph.D. was a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, an Associate Professor of Dermatology at Harvard Medical School for 25 years, and is now a Distinguished Visiting Professor at the University of Johannesburg, South Africa and affiliated faculty at Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran. He gained his PhD in organic chemistry from Nottingham Trent University in England. His research interests include photodynamic therapy, photobiomodulation, drug delivery, nanomedicine, and tissue engineering. His research program was supported by NIH, CDMRP, USAFOSR and CIMIT. He has published over 750 peer-reviewed articles, over 150 conference proceedings, book chapters and International abstracts and holds 10 patents. He is Editor-in-Chief of “Photobiomodulation, Photomedicine and Laser Surgery”, Associate Editor for 10 journals, on the editorial board of a further 60 journals. He has an h-factor 148 and > 88,000 citations. He has authored/edited 36 textbooks on PDT, photomedicine, and nanomedicine including 13 SPIE proceedings. Dr Hamblin was elected as a Fellow of SPIE in 2011, received the 1st Endre Mester Lifetime Achievement Award from NAALT in 2017, the Outstanding Career Award from the Dose Response Society, the 1st Ali Javan award for Photobiomodulation Basic Science Research from WALT in 2018, and the Lifetime Achievement Award from European Medical Laser Association in 2022.
Dr Alan Kwong Hing Chairman and Founder the Founder of PBM Healing, graduated with his Doctor of Dental Surgery degree (with distinction) from the University of Western Ontario. He received the University Gold Medal and completed a concurrent master’s degree in Pathology. Dr. Al has earned multiple other degrees and received numerous awards, including the pre–Doctoral IADR Hatton award for his research on MRIs. He is a serial entrepreneur, had a diverse career as a solo dentist, and owned large multi-dental groups in Canada, the UK, and the US. He has owned dental labs and specialized orthodontic labs, a dental model company, and a company that manufactured orthodontic wires and accessories. He was a KOL for NobelBiocare for many years and worked with the team to develop the NobelBiocare Replace Implant. He ran a mini dental residency to train dentists and their teams in dental implant surgery and restorative procedures. He enjoys lecturing worldwide, focusing on applying Photobiomodulation in medicine and dentistry. Most notable is the application of PBM principles in the medical and dental devices that he has developed to help alleviate pain and enhance healing. He also lectures on personal and practice development in his role as a Coach. He is a published author, most notably for the “E Myth Dentist” with Michael Gerber. His current book on General principles of Photobiomodulation is in its final draft stages.
Samuel Faveur CEO He is the CEO of PBM Healing, a Founding Partner, Director, and Chief Executive Officer of Mandarin Capital Ltd, a Hong Kong-based asset Management and advisory Company specialising in start ups and growth stage technology companies. Samuel began his career in 1999 as a research analyst for ING Barings in London before moving to ING Barings’ proprietary and market trading convertible bond desk. He was transferred to the Tokyo office in 2001 and, in 2003, joined Mizuho Securities in Hong Kong as Head of Asset Management. In this role, Samuel was tasked with setting up an internal hedge fund platform and managing two funds specializing in convertible bonds and volatility investments and additionally designed and implemented trading and operations infrastructures. By the time Samuel left Mizuho Securities in 2010, he had held the title of Head of Asset Management and was registered Responsible Officer: Type 9. In 2011 Samuel briefly joined MF Global as Head of Derivatives with proprietary and client facilitation mandates. Before setting up Mandarin Capital Ltd in 2012, Sam held the position of Managing Director and Portfolio Manager at Richmond Asset Management.